Abstract
Background: Differentiated thyroid carcinoma (DTC), which includes the papillary and follicular variants, is a common neoplasm. DTC has a very high cure rate and is treated surgically, usually followed by ablation of the post-surgical remnant with radioiodine. Case Presentation: The case of a 68-year-old male patient who underwent a minimally invasive complete thyroidectomy on July 4, 2007 for capsulated follicular carcinoma with margins of excision exempted from neoplastic infiltration (AJCC 2002 pT2 PNX PMX) is presented. Discussion: As the patient showed the presence of a pulmonary metastasis after 11 years, the potential implications of DTC follow-up management are here summarized. Conclusions: Follow up must be continued throughout life.
Highlights
Differentiated thyroid carcinoma, which includes the papillary and follicular variants, is a common neoplasm whose incidence has increased in recent years, probably due to heightened medical surveillance and more addressability to surgery
In February 2018 the patient underwent a new course of 131I therapy after systems (Tumor, Nodes, Metastases), the AGES (Age, Grade, Extent, Size), the MACIS (Metastases, stimulation with Recombinant human TSH (rh-TSH) (0.9 mg i.m.); on the second day the serum Tg values reached 10.77 ng/mL
The postoperative evaluation of the serum Tg test is recommended
Summary
Differentiated thyroid carcinoma, which includes the papillary and follicular variants, is a common neoplasm whose incidence has increased in recent years, probably due to heightened medical surveillance and more addressability to surgery. In this way, many cancers are diagnosed while under one cm [1]. The 10-year overall survival rates for papillary and follicular carcinomas are reported in many cases of 93% and 85%, respectively, with a weak dependence on age or differentiation of the tumor. The risk of persistent or recurrent disease must be reassessed depending on the initial therapy response [12,13,14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
